๐ข Our CEO, Dave Mullarkey, has authored a new expert article in Technology Networks:
For Actionable Drug Information, Consider Dynamic Epigenetics Data
www.technologynetworks.com/genomics/art...
@clearnotehealth.bsky.social
ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives.
๐ข Our CEO, Dave Mullarkey, has authored a new expert article in Technology Networks:
For Actionable Drug Information, Consider Dynamic Epigenetics Data
www.technologynetworks.com/genomics/art...
Don't miss us at @myesmo.bsky.social 2025!
Our team and collaborators will present new epigenomic research spanning multicancer detection, pancreatic cancer surveillance, and therapy monitoring.
#epigenomics #earlycancerdetection
๐ข Press Release: ClearNote Health Receives In Vitro Diagnostic Approval in United Kingdom for Avantectยฎ Multi-Cancer Detection Test and Avantectยฎ Ovarian Cancer Test
www.clearnotehealth.com/press-releas...
โจ Today is World Cancer Research Day!
Our mission to advance earlier and more accurate cancer detection is powered by a strong track record of scientific innovation and collaboration.
Learn more about our work: www.clearnotehealth.com
#cancerresearch #cancer
Our incredible Vice President of Laboratory Operations, Shimul Chowdhury, PhD, FACMG, recently shared a personal reflection on a career dedicated to early detection - from rapid sequencing in newborns to helping build ClearNoteโs clinical lab.
www.linkedin.com/pulse/era-ge...
#cancer
Proud to be an expertise partner of the 15th World CB & CDx Summit Sept 22-25 | Boston, MA
Meet our team at Booth #16 and discover how ClearNote Health's Virtuoso Platform is empowering more efficient oncology #drugdiscovery and development.
๐ Schedule a meeting: partnering@clearnotehealth.com
๐ข Donโt miss our presentation at the 17th Annual Next Generation Summit, Aug 18-20, Washington, D.C.
Talk Title: Epigenomic Signals Enable Early Cancer Detection in Liquid Biopsies
When: Monday, August 18 โ 9:00 am
Presenter: Anna Bergamaschi, PhD, Vice President Product R&D, ClearNote Health
According to a review recently published in #JAMA, gastrointestinal cancers have become the fastest-growing type of cancers diagnosed in adults younger than 50 in the U.S.
Read the article here: www.nbcnews.com/health/healt...
๐ข We are happy to announce that ClearNote Health has received UK Conformity Assessed (UKCA) marking for its Avantectยฎ Pancreatic Cancer Test.
www.clearnotehealth.com/press-releas...
๐ข Press Release: ClearNote Health Avantectยฎ Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients
With up to 15,000 patient participants, it will be the largest study of its kind!
www.clearnotehealth.com/press-releas...
#pancreaticcancer
It was a privilege to connect with so many in the oncology community at #ASCO25.
We were proud to share how our Virtuoso #epigenomics platform is redefining whatโs possible for more efficient and effective #drugdevelopment.
A big thank you to everyone who attended our poster presentation.
๐ข Don't miss our poster presentation at @ascocancer.bsky.social 2025
#ASCO25 #cancerbiology #epigenomics
In a recently published article in Diagnostics World, our CEO Dave Mullarkey shares how a stepping-stone approach, starting with single-cancer tests targeting high-mortality cancers, can lay the groundwork for broad, multi-cancer early detection.
www.diagnosticsworldnews.com/news/2025/05...
#MCED
๐ข Press Release: Human Longevity, Inc., Expands Cancer Prevention Offering by Selecting the ClearNote Health Avantectยฎ Early Detection #PancreaticCancer Test.
www.prnewswire.com/news-release...
Meet Our Chief Scientific Officer, Dr. Sam Levy, at #DDW25!
Speak with Dr. Levy at our booth to learn how ClearNote Health is harnessing the power of the epigenome to drive early #pancreaticcancer detection and transform patient outcomes.
๐ Location: Booth 5525
๐
When: May 4th & 5th, 12:00-2:00pm
Join ClearNote Health at Digestive Disease Week (#DDW) in San Diego May 406, where weโll be showcasing the #Avantect Pancreatic Cancer Test - a groundbreaking epigenomic liquid biopsy designed to aid in the early detection of pancreatic cancer.
Visit us at booth 5525
Last week, we proudly celebrated National Medical Laboratory Professionals Week at ClearNote Health! ๐
A huge thank you to our tremendous laboratory team for their on-going commitment and dedication to our mission of saving lives through earlier detection of cancer.
#LabWeek
ClearNote Health will be showcasing the latest advancements in tumor subtyping and circulating tumor fraction technologies at the @theaacr.bsky.social Annual Meeting 2025.
Learn more: www.clearnotehealth.com/press-releas...
#epigenomics #drugdevelopment
๐ข We will be at the @theaacr.bsky.social Annual Meeting '25, 25-30/04, Chicago.
Discover how our Virtuoso Epigenomics Platform is empowering more efficient oncology #drugdiscovery & development by leveraging 5hmC #epigenomic profiling to uncover active cancer biology patterns from #cfDNA in plasma.